Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Explore this paper's citation graph
Summary
A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.
- Type
- article
- Published
- 2019-11-01
- Cited by
- 2,635
- References
- 30
- Access
- Open access
- OpenAlex
- https://openalex.org/W2986633517
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:207811859
Keywords
Cetuximab, Pembrolizumab, Medicine, Chemotherapy, Head and neck
References
- In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
- The Efficiency of Cox's Likelihood Function for Censored Data
- Multiple Testing in Group Sequential Trials Using Graphical Approaches
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Platinum-based chemotherapy plus cetuximab in head and neck cancer.
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
- Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
- Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
- Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
Cited by
- PD-1 inhibition enters the frontline
- PD-1 immunotherapy for recurrent or metastatic HNSCC.
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.
- Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma
- Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects
- Immune landscape of viral- and carcinogen-driven head and neck cancer
- A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
- Biomarkers for immunotherapy response in head and neck cancer.
- Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
- Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
- A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
- Chemotherapy Plus Immune Check-Point Inhibitors in Metastatic Bladder Cancer
- Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors
- The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments
- Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
- Last-line Local Treatment with the Quad Shot Regimen for Previously Irradiated Head and Neck Cancers
- Overcoming frailty in recurrent and metastatic head and neck cancer.
- CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck
- Long-Term Update of NRG Oncology RTOG 0522: A Randomized Phase III Trial of Concurrent Radiation and Cisplatin with or without Cetuximab in Locoregionally Advanced Head and Neck Cancer
Related papers
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC)
- Data from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
- Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrc
- Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma
- The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
- Should cetuximab replace cisplatin in head and neck cancer?
- Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
- Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short‐term culture of tumor slices